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There has been a lot of hype over the use of PET in oncology, with
hopes that it will provide many answers in clinical research.
However, now it has been brought to the attention of clinicians and
oncology researchers, it is time to get down to the hard work of
exploring its potential and defining its true role.
In this edition of the BJC, a paper by Maisey et al (2000)
explores the use of 18F-FDG PET in predicting survival in patients
with cancer of the pancreas following systemic chemotherapy.
This is one in a series of similar papers that have been published
by various groups over the last 4 or 5 years seeking to find the
value of FDG PET in measuring response to therapy. So how far
have we got?
What PET is
Positron emission tomography (PET) is a technique which uses
radionuclides to label molecules. The molecules can then be
imaged in man and this provides quantitative kinetic functional
information. The inherent sensitivity and specificity of PET
methodology is the most important strength of the technique. Its
sensitivity is unrivalled and it can be used to image molecular
interactions and pathways, providing quantitative kinetic informa-
tion down to the sub-pico molar level (Jones, 1996). It lacks the
spatial resolution of MRI or CT, but as it is unrivalled in its speci-
ficity and kinetic sensitivity, it has a huge future for translation
research in oncology (Price, 1997).
Molecular imaging using PET is now being developed to assess
in vivo pharmacokinetics and pharmacodynamics in oncology
(Young et al, 1999a; Saleem et al, 2000). However, currently few
groups internationally have the range of expertise in radio-
chemistry, data analysis, bio-mathematical modelling and kinetic
analysis to advance and exploit the technique for these purposes,
so progress has been slow. PET methodology is better developed
in neurology and psychiatry, but it is still in its infancy in
oncology.
Current diagnostic use of PET
To most of the oncology community, PET is understood to be
static  18F-FDG images of tumours. This is because the vast
majority of work that has been performed in PET in oncology has
been using 18F-FDG. FDG (fluorodeoxyglucose) is an analogue of
glucose which is taken up into cells by GLUT 1 transporters and
trapped, as it is not metabolized by hexokinase. When FDG is
labelled with fluorine-18, its kinetics can be imaged with PET and
the resultant signal indicates glucose uptake and trapping. If static
images are taken at a certain time (say 45 min post-injection) then
images show hot-spots in tumours. Much of the work over the last
10 years has looked at the value of FDG as a diagnostic tool. This
is on the basis that FDG is preferentially taken up into tumour cells
and so from the differential uptake one can define malignant vs
non-malignant disease. There are controversies in its use in diag-
nosis and to what extent it can replace conventional anatomical
imaging (Price, 2000).
Cameras for whole-body imaging have been developed in the
last few years and so patient scanning can produce a ‘soft tissue
bone scan’. These images are convincing. However, the technique
can produce a number of false-positives, for example, 18F-FDG is
taken up into macrophages, and muscle uptake after exercise can
be high. It currently also provides no anatomical resolution. The
technique is being promoted by the nuclear medicine community
to the oncologists for diagnostic imaging and staging. In the USA
there are now five reimbursable indications for 18F-FDG: investi-
gation of solitary pulmonary nodules, staging of lung cancer,
investigation of a rising plasma CEA after colorectal surgery,
restaging of melanoma and restaging of lymphoma. The expansion
of the use of FDG PET for such diagnosis has been due to FDA
approval of 18F-FDG and its distribution, patient advocacy and
arguments of cost-effectiveness. In Europe its use is patchy, being
large in Germany, and is dependent on the number of centres in a
country and the mechanism of reimbursement. In the UK its use in
diagnosis is restricted to a few centres who have equipment and
who can devise a funding mechanism to cover the costs. Currently
in the UK the cost of a whole-body PET scan is in the region of
£800. The argument for the use of 18F-FDG PET in the UK for
diagnosis rests on its priority and cost-effectiveness in a resource-
scarce National Health Service.
PET as a quantitative technique
The field needs to move on to make use of the quantitative value
of PET. The use of easily achieved static non-objectively quantita-
tive FDG uptake (hot-spots) is insufficient to communicate objec-
tive change and is too insensitive to measure the important small
changes. Many studies heralding ‘hot-spot before, no hot-spot
after’ in successful treatments such as in chemotherapy for
lymphoma do little to demonstrate the unique value of the tech-
nique. We need information over and above obvious volume and
clinical changes.
The rate of 18F-FDG uptake into tissues and tumours can be
determined and a glucose metabolic rate (MRGlu) measured in
mmol min–1 ml–1 or standard uptake value (SUV) estimated. These
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FDG PET can be used as a prognostic marker and used to predict
survival. As this technique can be repeated before and after treat-
ment it can also be used to look at changes in response to therapy
and investigate whether such changes can predict ultimate clinical
outcome. As in vivo FDG uptake is broadly related to cell number
(Herholz et al, 1993), this can be taken further. Investigations are
underway to see whether the change after treatment can be used as
a measure of log cell kill and therefore provide a guide to sub-
clinical and clinical response (Price and Jones, 1995).
PET to measure tumour response: a consensus
statement from Europe
The use of FDG PET to measure tumour response is increasing
and new papers are being published all the time. In an attempt to
be able to pool quantitative data and move the field on more
quickly, the EORTC PET Study Group has held a consensus
conference in 1999 and reviewed the published and unpublished
literature on the subject. They come to recommendations for the
use of 18F-FDG to assess response (Young et al, 1999b). In this
paper, recommendations are provided on the scanning protocols
(such as fasting state of the patients, hydration, medication,
etc.), the timing of the scan, the type of scan used and the
method of assessment of 18F-FDG uptake, as well as tumour
sampling. The recommendations suggest a definition of 18F-
FDG tumour response in terms of complete, partial metabolic
response and stable and progressive metabolic disease. It is only
once we have standardized data collection that we can make
comparative statements and the field really moves on. These
recommendations will now be used for all the EORTC-approved
drug development studies using 18F-FDG PET as a pharmacody-
namic measure of anti-proliferative response. The Cancer
Research Campaign New Agents Committee are in the process
of adopting the EORTC guidelines for its own studies. The
National Cancer Institute in the USA will be holding a meeting
in June 2000 to decide theirs.
As with all technology that assesses change, the reproducibility
of the technique is extremely important. Precious little data on this
exists and papers commenting on changes in response to therapy
really need control test-re-test data for validity. One PET group in
Munich have usefully reported on their reproducibility in 16
patients (Weber et al, 1999). Only by expanding the test-re-test
database can we investigate the physiology of the noise in the
signal and develop the methodology.
The potential of 18F-FDG PET as a metabolic response
marker
Prediction of clinical response
From the data so far available in the world, some of it unpublished
as yet, it would appear that changes in FDG in response to therapy,
when performed accurately, can precede clinical response. This is
particularly useful in some instances where these measurements
can be taken very early on. In a paper by Brock et al (2000) FDG
PET measurements of MRGlu in brain tumours recorded at 7 days
were found to be able to predict ultimate clinical and radiological
response to chemotherapy recorded at 2 months. There is now
published breast cancer data suggesting that this also may be true
at other tumour sites (Smith et al 2000, Schelling et al 2000). The
use of 18F-FDG PET in the neoadjuvant setting may be very impor-
tant – particularly for identifying non-responders early.
Measurement of subclinical response
Whether changes in 18F-FDG PET can be used as a measure of
subclinical response is still unclear. The level with which this tech-
nique can measure response that does not appear clinically or
radiologically, and yet which is outside the normal reproducibility
ranges is unclear. Its use in phase I setting to measure subclinical
response has yet to be outlined. An EORTC two-centre study used
this technique in a phase I study and is currently in preparation for
reporting. One disadvantage may be the range of glucose metabo-
lism in different tumour types which may confound its use in a
phase I clinical trial where a range of tumour types are assessed.
Measurement of the additive effect of therapy
Other areas where such a quantitative early readout may be useful
is in situations where you are adding therapy. A quantitative
readout of the effect of one therapy can then be compared with that
of a two-therapy treatment. Currently at our institution we are
undertaking a study looking at the additional effects of temozolo-
mide to radiotherapy and assessing whether we can quantitate this
additional benefit using 18F-FDG PET.
Measurement of residual disease
There are many clinical situations where this may prove useful.
FDG assessment of ‘disease’ will not overtake a histological diag-
nosis, but for instance the identification of residual disease after
high-dose radiotherapy may allow small volume boosts in treat-
ment. Work in this area is needed.
Conclusion
18F-FDG PET provides a good signal, can be performed in many
centres, and its quantitation is based on mature kinetic modelling.
However, there are many difficulties in its use, not least of which is
that it is not completely tumour-specific. More work is needed by
methodologically competent groups in collaboration with good clin-
ical groups to further define its role. As clinicians, we have a respon-
sibility, as the more we understand of the methodology ourselves the
more we will be able to put it to appropriate use and ensure the accu-
racy and validity of what we are measuring. Advice is available. The
CRC drug development section has a pharmacokinetic/pharmaco-
dynamic (PK/PD) committee which provides advice on such end-
points. The EORTC have a Functional Imaging group which can
also provide information to academia and industry.
The future
We need more specific markers with high sensitivity which we can
use for specific pharmacodynamic end-points. Markers specifi-
cally for anti-proliferative therapy, such as 11C-thymidine and 18F-
FLT, are currently under development. Measures such as H2
15O
and both C15O to measure tumour perfusion, and blood volume are
being developed to assess anti-angiogenic and anti-vascular
therapy. Methodological improvements are required, such as high
sensitivity cameras, increased ability to co-register images, good
radiochemistry and kinetic methodological development.
We also must remember that PET has much wider potential for
in vivo pharmacokinetic measurements and the investigation of
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need more effort put into the methodological development, that
leads on to good applications, before this technology will truly
reap the rewards of its potential.
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